For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

Last summer, Harvard researchers revealed a troubling link between semaglutide, the active ingredient in Ozempic and Wegovy, and non-arteritic anterior ischemic optic neuropathy (NAION), a ...

The condition, known as non-arteritic anterior ischemic optic neuropathy, occurs when blood flow to the optic nerve becomes compromised.

While most mild side effects are temporary, some serious side effects like non-arteritic anterior ischemic optic neuropathy (NAION) and priapism can lead to long-term health issues if not promptly ...